Last reviewed · How we verify
APVAC1 vaccine plus Poly-ICLC and GM-CSF
APVAC1 vaccine targets tumor antigens, Poly-ICLC is a Toll-like receptor 3 agonist, and GM-CSF is a granulocyte-macrophage colony-stimulating factor.
APVAC1 vaccine targets tumor antigens, Poly-ICLC is a Toll-like receptor 3 agonist, and GM-CSF is a granulocyte-macrophage colony-stimulating factor. Used for Non-small cell lung cancer, Melanoma.
At a glance
| Generic name | APVAC1 vaccine plus Poly-ICLC and GM-CSF |
|---|---|
| Also known as | Actively Personalized Vaccine, Hiltonol, Leukine |
| Sponsor | Immatics Biotechnologies GmbH |
| Drug class | Personalized neoantigen vaccine |
| Target | Tumor antigens |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
APVAC1 vaccine is a personalized neoantigen vaccine that targets tumor-specific antigens, Poly-ICLC is an adjuvant that stimulates the innate immune response through Toll-like receptor 3, and GM-CSF is a cytokine that promotes the activation and maturation of antigen-presenting cells.
Approved indications
- Non-small cell lung cancer
- Melanoma
Common side effects
- Injection site reaction
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: